TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway

TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway

Abstract Cancer is among the leading causes of death related diseases worldwide, and lung cancer has the highest mortality rate in the world. Transcription factors (TFs) constitute a class of structurally and functionally intricate proteins. Aberrant expression or functional deficiencies of transcri...

Full description

Saved in:
Bibliographic Details
Main Authors: Ding-Guo Wang, Jian Gao, Jing Wang, Kun-Chao Li, Zhi-Bo Wu, Zhong-Min Liao, Yong-Bing Wu
Format: Article
Language:English
Published: Nature Publishing Group 2024-12-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-024-02251-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items